• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接种 COVID-19 疫苗后吸氧人群中抗 SARS-CoV-2 S 抗体与 IFN-λ3 水平的关系。

Relationship between Anti-SARS-CoV-2 S Abs and IFN-λ3 Levels in the Administration of Oxygen following COVID-19 Vaccination.

机构信息

Department of Pulmonary Medicine, International University of Health and Welfare Narita Hospital, Narita, Chiba, Japan.

Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Itabashiku, Tokyo, Japan; and.

出版信息

Immunohorizons. 2023 Jan 1;7(1):97-105. doi: 10.4049/immunohorizons.2200093.

DOI:10.4049/immunohorizons.2200093
PMID:36645852
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10563441/
Abstract

Although the effectiveness of vaccination at preventing hospitalization and severe coronavirus disease (COVID-19) has been reported in numerous studies, the detailed mechanism of innate immunity occurring in host cells by breakthrough infection is unclear. One hundred forty-six patients were included in this study. To determine the effects of vaccination and past infection on innate immunity following SARS-CoV-2 infection, we analyzed the relationship between anti-SARS-CoV-2 S Abs and biomarkers associated with the deterioration of COVID-19 (IFN-λ3, C-reactive protein, lactate dehydrogenase, ferritin, procalcitonin, and D-dimer). Anti-S Abs were classified into two groups according to titer: high titer (≥250 U/ml) and low titer (<250 U/ml). A negative correlation was observed between anti-SARS-CoV-2 S Abs and IFN-λ3 levels (r = -0.437, p < 0.001). A low titer of anti-SARS-CoV-2 S Abs showed a significant association with oxygen demand in patients, excluding aspiration pneumonia. Finally, in a multivariate analysis, a low titer of anti-SARS-CoV-2 S Abs was an independent risk factor for oxygen demand, even after adjusting for age, sex, body mass index, aspiration pneumonia, and IFN-λ3 levels. In summary, measuring anti-SARS-CoV-2 S Abs and IFN-λ3 may have clinical significance for patients with COVID-19. To predict the oxygen demand of patients with COVID-19 after hospitalization, it is important to evaluate the computed tomography findings to determine whether the pneumonia is the result of COVID-19 or aspiration pneumonia.

摘要

尽管许多研究已经报道了疫苗接种在预防住院和严重冠状病毒病(COVID-19)方面的有效性,但突破性感染导致宿主细胞固有免疫的详细机制尚不清楚。本研究纳入了 146 名患者。为了确定疫苗接种和既往感染对 COVID-19 感染后固有免疫的影响,我们分析了 SARS-CoV-2 S 抗体与 COVID-19 恶化相关生物标志物(IFN-λ3、C 反应蛋白、乳酸脱氢酶、铁蛋白、降钙素原和 D-二聚体)之间的关系。根据滴度将抗 SARS-CoV-2 S 抗体分为高滴度(≥250 U/ml)和低滴度(<250 U/ml)两组。抗 SARS-CoV-2 S 抗体与 IFN-λ3 水平呈负相关(r = -0.437,p < 0.001)。低滴度的抗 SARS-CoV-2 S 抗体与患者的氧气需求显著相关,排除了吸入性肺炎。最后,在多变量分析中,即使在调整年龄、性别、体重指数、吸入性肺炎和 IFN-λ3 水平后,低滴度的抗 SARS-CoV-2 S 抗体仍是氧气需求的独立危险因素。综上所述,测量抗 SARS-CoV-2 S 抗体和 IFN-λ3 可能对 COVID-19 患者具有临床意义。为了预测 COVID-19 住院患者的氧气需求,评估计算机断层扫描结果以确定肺炎是否是 COVID-19 还是吸入性肺炎的结果很重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/873c/10563441/14342cda5f72/ih2200093f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/873c/10563441/93bcd60a1e77/ih2200093f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/873c/10563441/d3909f5a0927/ih2200093f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/873c/10563441/14342cda5f72/ih2200093f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/873c/10563441/93bcd60a1e77/ih2200093f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/873c/10563441/d3909f5a0927/ih2200093f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/873c/10563441/14342cda5f72/ih2200093f3.jpg

相似文献

1
Relationship between Anti-SARS-CoV-2 S Abs and IFN-λ3 Levels in the Administration of Oxygen following COVID-19 Vaccination.接种 COVID-19 疫苗后吸氧人群中抗 SARS-CoV-2 S 抗体与 IFN-λ3 水平的关系。
Immunohorizons. 2023 Jan 1;7(1):97-105. doi: 10.4049/immunohorizons.2200093.
2
Age-Related Expression of IFN-λ1 IFN-I and Beta-Defensins in the Nasopharynx of SARS-CoV-2-Infected Individuals.年龄相关性 IFN-λ1、IFN-I 和 β 防御素在 SARS-CoV-2 感染个体鼻咽部的表达。
Front Immunol. 2021 Nov 10;12:750279. doi: 10.3389/fimmu.2021.750279. eCollection 2021.
3
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
4
Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.维持性透析患者接种 SARS-CoV-2 疫苗后 6 个月的血清学反应。
Clin J Am Soc Nephrol. 2022 Mar;17(3):403-413. doi: 10.2215/CJN.12250921. Epub 2022 Feb 10.
5
Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma.SARS-CoV-2 肺炎患者接受高滴度恢复期血浆治疗的临床和实验室评估。
JCI Insight. 2021 Mar 22;6(6):143196. doi: 10.1172/jci.insight.143196.
6
More rapid blood interferon α2 decline in fatal versus surviving COVID-19 patients.COVID-19 死亡患者与存活患者的血液干扰素 α2 下降更快。
Front Immunol. 2023 Nov 21;14:1250214. doi: 10.3389/fimmu.2023.1250214. eCollection 2023.
7
Association Between Low Anti-spike Antibody Levels After the Third Dose of SARS-CoV-2 Vaccination and Hospitalization due to Symptomatic Breakthrough Infection in Kidney Transplant Recipients.第三剂 SARS-CoV-2 疫苗接种后低抗刺突抗体水平与肾移植受者因有症状突破感染而住院之间的关联。
Ann Lab Med. 2024 Jan 1;44(1):64-73. doi: 10.3343/alm.2024.44.1.64. Epub 2023 Sep 4.
8
Pathogenesis-directed therapy of 2019 novel coronavirus disease.针对 2019 新型冠状病毒病的发病机制导向治疗。
J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10.
9
Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL).根据世界卫生组织国际结合抗体单位(BAU/mL),自然感染和随后接种疫苗后对 SARS-CoV-2 的长期体液免疫反应。
Viruses. 2021 Nov 23;13(12):2336. doi: 10.3390/v13122336.
10
Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients.SARS-CoV-2 特异性抗体分泌细胞的扩增和住院 COVID-19 患者中中和抗体的产生。
J Immunol. 2020 Nov 1;205(9):2437-2446. doi: 10.4049/jimmunol.2000717. Epub 2020 Sep 2.

本文引用的文献

1
Performance evaluation of the Roche Elecsys® Anti-SARS-CoV-2 immunoassays by comparison with neutralizing antibodies and clinical assessment.罗氏 Elecsys®抗 SARS-CoV-2 免疫分析的性能评估与中和抗体和临床评估的比较。
PLoS One. 2022 Sep 15;17(9):e0274181. doi: 10.1371/journal.pone.0274181. eCollection 2022.
2
Prediction of the possibility of return to home based on frailty assessment at the time of admission to the COVID-19 treatment unit.基于新冠治疗病房入院时的衰弱评估预测回家可能性
Geriatr Gerontol Int. 2022 Sep;22(9):815-817. doi: 10.1111/ggi.14460. Epub 2022 Aug 12.
3
Interferon lambda 3 in the early phase of coronavirus disease-19 can predict oxygen requirement.
新型冠状病毒肺炎早期的干扰素λ3可预测氧需求。
Eur J Clin Invest. 2022 Sep;52(9):e13808. doi: 10.1111/eci.13808. Epub 2022 May 12.
4
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.Covid-19 疫苗对奥密克戎(B.1.1.529)变异株的有效性。
N Engl J Med. 2022 Apr 21;386(16):1532-1546. doi: 10.1056/NEJMoa2119451. Epub 2022 Mar 2.
5
Measurement of SARS-CoV-2 Antibody Titers Improves the Prediction Accuracy of COVID-19 Maximum Severity by Machine Learning in Non-Vaccinated Patients.基于机器学习的非接种患者 SARS-CoV-2 抗体滴度测量可提高 COVID-19 严重程度的预测精度。
Front Immunol. 2022 Jan 21;13:811952. doi: 10.3389/fimmu.2022.811952. eCollection 2022.
6
Receiver operating characteristic curve: overview and practical use for clinicians.受试者工作特征曲线:概述与临床医师的实际应用
Korean J Anesthesiol. 2022 Feb;75(1):25-36. doi: 10.4097/kja.21209. Epub 2022 Jan 18.
7
Innate immunity: the first line of defense against SARS-CoV-2.先天免疫:抵御 SARS-CoV-2 的第一道防线。
Nat Immunol. 2022 Feb;23(2):165-176. doi: 10.1038/s41590-021-01091-0. Epub 2022 Feb 1.
8
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.辉瑞-BioNTech 信使核糖核酸 COVID-19 疫苗在美国大型综合卫生系统中的 6 个月有效性:一项回顾性队列研究。
Lancet. 2021 Oct 16;398(10309):1407-1416. doi: 10.1016/S0140-6736(21)02183-8. Epub 2021 Oct 4.
9
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar.卡塔尔:BNT162b2 疫苗对 SARS-CoV-2 感染的保护作用逐渐减弱。
N Engl J Med. 2021 Dec 9;385(24):e83. doi: 10.1056/NEJMoa2114114. Epub 2021 Oct 6.
10
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.辉瑞-BioNTech 信使核糖核酸新冠病毒疫苗 6 个月的安全性和有效性
N Engl J Med. 2021 Nov 4;385(19):1761-1773. doi: 10.1056/NEJMoa2110345. Epub 2021 Sep 15.